GlassScriptPhysician profile
Paul Enochs
NPI 1558339036
$594,735.08
in general payments reported to CMS, 2019-2025
31 companies · $68K in 2025
The $68K reported for 2025 was more than what 99% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56K · 2020: $85K · 2021: $178K · 2022: $80K · 2023: $73K · 2024: $55K · 2025: $68K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $140K · Travel and Lodging: $19K · Consulting Fee: $15K · Education: $8,000 · Food and Beverage: $7,944 · Acquisitions: $6,662.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $139,618.75 |
| Travel and Lodging | $19,408.76 |
| Consulting Fee | $14,712.50 |
| Education | $8,000.00 |
| Food and Beverage | $7,943.70 |
| Acquisitions | $6,661.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $263,740.98 | 2019-2025 | Da Vinci Surgical System |
| Teleflex LLC | $202,468.18 | 2020-2025 | Titan Sgs Standard Gastric Stapler, Titan Sgs Bailout Chuck, Titan Sgs |
| Standard Bariatrics, INC. | $76,143.18 | 2019-2023 | Titan Sgs Standard Gastric Stapler |
| Medical Device Business Services, INC. | $15,850.30 | 2019-2021 | |
| W. L. Gore & Associates, INC. | $11,722.79 | 2019-2023 | Gore Seamguard Bioabsorbable Staple Line Reinforce |
| Gt Metabolic Solutions INC | $10,000.00 | 2025 | |
| Ethicon INC. | $2,900.00 | 2021 | |
| Smith+Nephew, INC. | $2,846.59 | 2019 | |
| Medtronic, INC. | $2,665.38 | 2022-2025 | Signia |
| Teleflex Medical Incorporated | $2,261.94 | 2021-2023 | Titan Sgs Standard Gastric Stapler |
| Covidien LP | $1,376.55 | 2019-2020 | |
| Endolumik, INC. | $700.00 | 2024 | Endolumik Gastric Calibration Tube |
| Ethicon US, LLC | $460.01 | 2019-2021 | |
| Activ Surgical, INC. | $438.74 | 2023-2024 | Activsight |
| Endo Pharmaceuticals INC. | $205.96 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Levita Magnetics International Corp | $188.58 | 2019 | |
| Baxter Healthcare | $153.24 | 2024 | Tisseel |
| Aesculap, INC. | $136.08 | 2019 | |
| Reshape Lifesciences INC. | $125.00 | 2021 | |
| Tela Bio, INC. | $52.64 | 2021 | |
| Novo Nordisk INC | $47.06 | 2025 | Wegovy |
| Intra-Sana Laboratories | $40.83 | 2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Takeda Pharmaceuticals U.S.A., INC. | $36.62 | 2022-2023 | Gattex |
| Tricoast Surgical Solutions LLC | $32.85 | 2025 | |
| Acacia Pharma INC | $31.42 | 2021 | |
| Merck Sharp & Dohme LLC | $23.14 | 2019 | |
| Redhill Biopharma INC. | $23.11 | 2021 | |
| Nestle Healthcare Nutrition INC. | $19.52 | 2021 | |
| Daiichi Sankyo INC. | $19.25 | 2022 | |
| Abbvie INC. | $13.28 | 2021 | |
| Vivus LLC | $11.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$60,272.30 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Enochs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.